Class information for:
Level 1: BORTEZOMIB//PROTEASOME INHIBITOR//PROTEASOME INHIBITORS

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
5442 1557 47.0 90%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
873 10811 PROTEASOME//UBIQUITIN//NEDD8

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BORTEZOMIB Author keyword 77 21% 21% 320
2 PROTEASOME INHIBITOR Author keyword 64 32% 11% 166
3 PROTEASOME INHIBITORS Author keyword 37 31% 6% 100
4 PS 341 Author keyword 18 51% 2% 25
5 PROTEASOME INHIBITION Author keyword 14 24% 3% 52
6 CARFILZOMIB Author keyword 13 39% 2% 27
7 MARIZOMIB Author keyword 12 75% 1% 9
8 CEP 18770 Author keyword 11 100% 0% 6
9 SYRBACTIN Author keyword 11 100% 0% 6
10 SYRINGOLIN Author keyword 9 83% 0% 5

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 BORTEZOMIB 77 21% 21% 320 Search BORTEZOMIB Search BORTEZOMIB
2 PROTEASOME INHIBITOR 64 32% 11% 166 Search PROTEASOME+INHIBITOR Search PROTEASOME+INHIBITOR
3 PROTEASOME INHIBITORS 37 31% 6% 100 Search PROTEASOME+INHIBITORS Search PROTEASOME+INHIBITORS
4 PS 341 18 51% 2% 25 Search PS+341 Search PS+341
5 PROTEASOME INHIBITION 14 24% 3% 52 Search PROTEASOME+INHIBITION Search PROTEASOME+INHIBITION
6 CARFILZOMIB 13 39% 2% 27 Search CARFILZOMIB Search CARFILZOMIB
7 MARIZOMIB 12 75% 1% 9 Search MARIZOMIB Search MARIZOMIB
8 CEP 18770 11 100% 0% 6 Search CEP+18770 Search CEP+18770
9 SYRBACTIN 11 100% 0% 6 Search SYRBACTIN Search SYRBACTIN
10 SYRINGOLIN 9 83% 0% 5 Search SYRINGOLIN Search SYRINGOLIN

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 PS 341 148 68% 8% 129
2 BORTEZOMIB 42 16% 15% 238
3 PROTEASOME INHIBITOR BORTEZOMIB 40 25% 9% 140
4 MULTIPLE MYELOMA CELLS 40 18% 13% 200
5 CHYMOTRYPSIN LIKE ACTIVITY 32 47% 3% 51
6 PROTEASOME INHIBITOR PS 341 27 26% 6% 89
7 20S PROTEASOME 26 14% 11% 174
8 PR 171 24 82% 1% 14
9 TMC 95A ANALOGS 19 80% 1% 12
10 PSMB5 18 83% 1% 10

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
The ubiquitin-proteasome system: opportunities for therapeutic intervention in solid tumors 2015 5 141 45%
Molecular basis of resistance to proteasome inhibitors in hematological malignancies 2015 4 186 38%
Proteasome Inhibitors: An Expanding Army Attacking a Unique Target 2012 133 142 64%
Building on bortezomib: second-generation proteasome inhibitors as anti-cancer therapy 2010 116 37 65%
Bortezomib as the First Proteasome Inhibitor Anticancer Drug: Current Status and Future Perspectives 2011 146 154 49%
The development of proteasome inhibitors as anticancer drugs 2004 441 47 72%
Proteasome inhibitors in cancer therapy: Lessons from the first decade 2008 294 106 43%
New orally active proteasome inhibitors in multiple myeloma 2014 6 66 64%
The proteasome: A suitable antineoplastic target 2004 662 131 36%
A first in human phase I study of the proteasome inhibitor CEP-18770 in patients with advanced solid tumours and multiple myeloma 2013 20 12 67%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 BIOMETRY STAT ANAL 4 75% 0.2% 3
2 ZENTRUM MED BIOTECHNOL 3 20% 1.0% 15
3 CHILDRENS CANC HOSP MD ANDERSON 2 67% 0.1% 2
4 PROGRAM HEMATOL ONCOL 2 67% 0.1% 2
5 JEROME LIPPER MYELOMA MED ONCOL 2 36% 0.3% 4
6 FRED WYSZKOWSKI CANC 2 17% 0.6% 9
7 EDUC DRUG DISCOVERY 2 22% 0.4% 6
8 BIOCIS UMR CNRS 8076 1 38% 0.2% 3
9 LYMPHOMA DEV CHEMOTHER Y SERV 1 38% 0.2% 3
10 ADULT BLOOD MARROW TRANSPLANTAT 1 100% 0.1% 2

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000202518 PROTEASOME//MULTICATALYTIC PROTEINASE//PA28
2 0.0000172409 SALINOSPORAMIDE A//KAITOCEPHALIN//SALINISPORA TROPICA
3 0.0000114367 NELFINAVIR//SAQUINAVIR NO//ANTIRETROVIRALL THERAPY
4 0.0000101175 MULTIPLE MYELOMA//LENALIDOMIDE//BORTEZOMIB
5 0.0000080569 MYELOMA BONE DISEASE//CAM DR//HEIM
6 0.0000075849 QILIQIANGXIN//DESMIN RELATED CARDIOMYOPATHY//PROT QUAL CONTROL DE AT
7 0.0000056684 PUPYLATION//PROKARYOTIC UBIQUITIN LIKE PROTEIN//URM1
8 0.0000053958 MANTLE CELL LYMPHOMA//T1114//BCL 1
9 0.0000053215 I KAPPA B//IKK//C REL
10 0.0000052619 USP22//UCH L1//DEUBIQUITINATING ENZYME